Mobile

A Phase IIb, 12-week, multicenter, randomized, double-blind, placebo-controlled, pioglitazone-controlled, parallel-group dose-ranging study in approximately 336 male and female subjects, aged 18 to 70...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-004694-97

A Phase IIb, 12-week, multicenter, randomized, double-blind, placebo-controlled, pioglitazone-controlled, parallel-group dose-ranging study in approximately 336 male and female subjects, aged 18 to 70 years with type 2 diabetes mellitus who are treatment naïve

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The present study is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of GSK189075 and pioglitazone 30mg, compared to placebo, administered as monotherapy over 12 weeks in treatment naïve subjects with Type 2 Diabetes Mellitus.

Critère d'inclusion

  • Type 2 diabetes mellitus

Liens